- Healthcare and technology company InhaleRx (IRX) appoints Darryl Davies as CEO, effective immediately
- Mr Davies joined InhaleRx’s board in July 2021 and has over 16 years of experience in psychology, harm minimisation and healthcare commercialisation
- He launched Australia’s first university-partnered educational programs for the cannabis industry and has coordinated doctor education initiative across Australia
- Further, Dr Rob Jenny has been appointed Chief Scientific Officer while Dr John Crock has been appointed Non-Executive Director
- InhaleRx is up 6.67 per cent on the market with shares trading at 6.4 cents at 1:53 pm AEST
Healthcare and technology company InhaleRx (IRX) has appointed Darryl Davies as CEO, effective immediately.
Mr Davies joined InhaleRx’s board in July 2021 and has over 16 years of experience in psychology, harm minimisation and healthcare commercialisation.
He launched Australia’s first university-partnered educational programs for the cannabis industry and has coordinated doctor education initiative across Australia.
“I look forward to the next exciting chapter in InhaleRx’s development and I’ll be working closely with the highly credentialed board and management team in leading the execution of the company’s strategic plans across the lifecycle of the two clinical trial programmes,” Mr Davies commented.
“In addition, I’ll be focusing on new opportunities to develop novel inhalation drug/device therapies to address unmet clinical needs.”
Dr Rob Jenny has been appointed Chief Scientific Offer and will supervise two programs to oversee the scientific, regulatory and tech transfer process to ensure the trials are ready to begin.
Dr Jenny is a biochemist in training and has experience in research and development, pharma manufacturing and commercialisation.
He has been involved in multiple commercialisation initiatives with universities, start-ups and pharmaceutical and personal care manufacturers.
Further, Dr John Crock has been appointed Non-Executive Director and will advise on both upcoming programs.
He is a highly experienced plastic surgeon and has more than 40 years of experience.
Dr Crock is the founder of the international aid organisation Aussie Health Abroad and has practised as a clinical supervisor/clinical lecturer at Monash University.
InhaleRx was up 6.67 per cent on the market with shares trading at 6.4 cents at market close.